Profile
| Metric | Value |
|---|---|
| Full Name | Taysha Gene Therapies, Inc. |
| Ticker | NASDAQ: TSHA |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | tayshagtx.com |
| Employees | 73 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $5.31 | |
| Price, 1D Change | +0.95% | |
| Market Cap | $1B | |
| - | ||
| PE Ratio | - | |
| Beta | 1.12 | |
| Revenue | $8M | |
| Revenue, 1Y Change | -46.07% | |
| EPS | -$0.36 | |
| EPS, 1Y Change | +62.84% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$0.36 | |
| EPS Estimate | -$0.34 | |
| EPS Est. Change | +5.69% | |
| Revenue | $8.33M | |
| Revenue Estimate | $6.30M | |
| Revenue Est. Change | -24.39% | |
| Current Price | $5.31 | |
| Price Target | - | $10.50 |
| Price Tgt. Change | - | +97.74% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$1.47 | -$0.96 | +34.64% | |
| -$0.31 | -$0.36 | -15.16% | |
| -$0.34 | N/A | +5.69% | |
| -$0.44 | N/A | -22.69% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $14.48M | $15.45M | +6.71% | |
| $8.25M | $8.33M | +1.06% | |
| $6.30M | N/A | -24.39% | |
| $3.91M | N/A | -53.07% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +182.45% | |
| Price, 3Y | +164.18% | |
| Market Cap, 1Y | +277.51% | |
| Market Cap, 3Y | +1,044.86% | |
| Revenue, 1Y | -46.07% | |
| Revenue, 3Y | +100.00% | |
| EPS, 1Y | +62.84% | |
| EPS, 3Y | +92.30% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $5.31 | |
| SMA 200 | $3.29 | |
| SMA 200 vs Price | -38.06% | |
| SMA 50 | $4.90 | |
| SMA 50 vs Price | -7.82% | |
| Beta | 1.12 | |
| ATR | $0.35 | |
| 14-Day RSI | 50.55 | |
| 10-Day Volatility | 66.09% | |
| 1-Year Volatility | 99.37% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $8.33M | |
| EPS | -$0.36 | |
| Gross Profit | $7.09M | |
| Gross Margin | 85.06% | |
| Operating Profit | -$86.62M | |
| Operating Margin | -1,039.49% | |
| Net Income | -$89.30M | |
| Net Margin | -1,071.62% | |
| EBITDA | -$85.38M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.89 | |
| Current Ratio | 5.41 | |
| Quick Ratio | 5.42 | |
| - | ||
| F-Score | - | |
| Altman Z-Score | 0.71 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | 230.51 | |
| PB Ratio | 6.64 | |
| EV/EBITDA | -12.14 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $71.53M | |
| Cash & Equivalents | $139.04M | |
| Total Assets | $276.41M | |
| Current Assets | $142.13M | |
| Total Liabilities | $204.88M | |
| Current Liabilities | $26.23M | |
| Total Debt | $63.95M | |
| Short Term Debt | $1.88M | |
| Accounts Payable | $3.59M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $97.63M | |
| Operating Expenses | $93.71M | |
| Cost Of Goods Sold | $1.25M | |
| SG&A | $0.00 | |
| D&A | $1.25M | |
| Interest Expense | $0.00 | |
| Income Tax | $0.00 |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$81.23M | |
| CFI | -$363.00K | |
| CFF | $76.68M | |
| Capex | $374.00K | |
| Free Cash Flow | -$81.60M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Wells Fargo | → | |
| Citizens | → | |
| Chardan Capital | → | |
| Raymond James | ||
| Needham | → | |
| Chardan Capital | → | |
| Needham | → | |
| Baird | → | |
| Wells Fargo | → | |
| Canaccord Genuity | → |
Analyst sentiment
Institutional ownership
Screeners with TSHA
Data Sources & References
- TSHA Official Website www.tayshagtx.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1806310/000119312525263506/0001193125-25-263506-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1806310/000095017025027348/0000950170-25-027348-index.htm
- TSHA Profile on Yahoo Finance finance.yahoo.com/quote/TSHA
- TSHA Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/tsha
FAQ
What is the ticker symbol for Taysha Gene Therapies, Inc.?
The ticker symbol for Taysha Gene Therapies, Inc. is NASDAQ:TSHA
Does Taysha Gene Therapies, Inc. pay dividends?
No, Taysha Gene Therapies, Inc. does not pay dividends
What sector is Taysha Gene Therapies, Inc. in?
Taysha Gene Therapies, Inc. is in the Healthcare sector
What industry is Taysha Gene Therapies, Inc. in?
Taysha Gene Therapies, Inc. is in the Biotechnology industry
What country is Taysha Gene Therapies, Inc. based in?
Taysha Gene Therapies, Inc. is headquartered in United States
When did Taysha Gene Therapies, Inc. go public?
Taysha Gene Therapies, Inc. initial public offering (IPO) was on September 24, 2020
Is Taysha Gene Therapies, Inc. in the S&P 500?
No, Taysha Gene Therapies, Inc. is not included in the S&P 500 index
Is Taysha Gene Therapies, Inc. in the NASDAQ 100?
No, Taysha Gene Therapies, Inc. is not included in the NASDAQ 100 index
Is Taysha Gene Therapies, Inc. in the Dow Jones?
No, Taysha Gene Therapies, Inc. is not included in the Dow Jones index
When was Taysha Gene Therapies, Inc. last earnings report?
Taysha Gene Therapies, Inc.'s most recent earnings report was on November 4, 2025
When does Taysha Gene Therapies, Inc. report earnings?
The next expected earnings date for Taysha Gene Therapies, Inc. is February 25, 2026